Merck & Co., Inc. (MRK): A Bull Case Theory

We came across a bullish thesis on Merck & Co., Inc. (MRK) on Substack by Charly AI. In this article, we will summarize the bulls’ thesis on MRK. Merck & Co., Inc. (MRK)’s share was trading at $81.91 as of April 9^th. MRK’s trailing and forward P/E were 12.15 and 9.10 respectively according to Yahoo Finance.

David Smart/Shutterstock.com

Merck (MRK) is emerging from 2024 with strong momentum, posting 7% revenue growth fueled by its expanding oncology and cardiovascular franchises—key areas underpinning its future growth ambitions. The company’s operating efficiency is reflected in its gross margin improvement to 76.3%, aided by a favorable product mix and disciplined cost controls. Notably, strategic moves in oncology, including targeted acquisitions and partnerships, have deepened Merck’s competitive moat and laid the groundwork for sustained expansion. Net income surged to $17.1 billion, driven not only by top-line growth but also by a meaningful reduction in R&D expenses, signaling a maturation of past pipeline investments. Merck continues to generate impressive levels of free cash flow, with a 28% margin underscoring its cash-generating power. However, there is room to enhance capital efficiency, as indicated by a modest 0.41 return on equity. Its balance sheet reflects a higher financial risk profile with a debt-to-equity ratio of 0.83, yet growing cash reserves provide a cushion and improve its liquidity outlook. The company’s financial standing is further supported by the absence of shareholder dilution or impairment charges, reinforcing confidence in its capital discipline. Despite some balance sheet leverage, Merck’s operational and strategic execution places it in a favorable position for long-term value creation. The market has yet to fully appreciate the strength of its earnings power and durable growth drivers, presenting a mispricing opportunity. With resilient cash flows, improving margins, and strong positioning in high-value therapeutic categories, Merck offers investors a compelling entry point.

Merck & Co., Inc. (MRK) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 91 hedge fund portfolios held MRK at the end of the fourth quarter which was 86 in the previous quarter. While we acknowledge the risk and potential of MRK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than MRK but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.

Disclosure: None. This article was originally published at Insider Monkey.